GWP
BCYC

Gen-Wealth Partners’s Bicycle Therapeutics BCYC Stock Holding History

Gen-Wealth Partners’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-39
Closed -$789 – 662
2024
Q2 		$789 Hold
39
– – ﹤0.01% 604
2024
Q1 		$971 Buy
+39
New +$828 ﹤0.01% 587

Other funds holding BCYC

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Gen-Wealth Partners's BCYC Position: Q3 2024 in Review

Gen-Wealth Partners sold out of Bicycle Therapeutics (BCYC) in Q3 2024, closing a stake of 39 shares — an estimated $789 sold.

Gen-Wealth Partners first reported a position in BCYC in Q1 2024 and held it in 2 quarters. The position peaked at $971 in Q1 2024. 105 funds tracked by Wall St. Rank hold BCYC as of Q3 2024.

  • Gen-Wealth Partners reported no remaining Bicycle Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Gen-Wealth Partners sold 39 Bicycle Therapeutics shares in Q3 2024, an estimated $789.
  • Gen-Wealth Partners first reported a position in Bicycle Therapeutics in Q1 2024 and held it in 2 quarters.
  • Gen-Wealth Partners's Bicycle Therapeutics position peaked at $971 in Q1 2024.
  • 105 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q3 2024.

Based on Gen-Wealth Partners's 13F filing for Q3 2024, filed 13 Nov 2024.